Dr.Jen Walsh, Director of the UWA Centre for Sleep Science says that “it is exciting to be working with Incannex on this trial of an alternate treatment option. Even patients who can tolerate existing therapies for their OSA would sometimes like the option to take a medication, rather than sleep with a device.” Deloitte Access Economics estimated that the direct economic costs due to OSA in Australia are in excess of $21 billion per year. This is due to loss of productive work days and co-morbidities of OSA such as cardiovascular problems and depression.
IHL Price at posting:
55.5¢ Sentiment: Buy Disclosure: Held